Interaction risk with proton pump inhibitors in general practice: Significant disagreement between different drug-related information sources

British Journal of Clinical Pharmacology

Volumn 62, Issue 5, 2006, Pages 582-590

  Trifirò, Gianluca ^a   Corrao, Salvatore ^b   Alacqua, Marianna ^a   Moretti, Salvatore ^c   Tari, Michele ^c   Caputi, Achille P ^a   Arcoraci, Vincenzo ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c 'Caserta 1' Local Health Service   (Italy)

Author keywords

Drug information sources; Drug drug interaction; Drugdex; General practice; Proton pump inhibitors; Summary of Product Characteristics

Indexed keywords

ALUMINUM HYDROXIDE; AMPICILLIN; CARBAMAZEPINE; CITALOPRAM; CLARITHROMYCIN; CYANOCOBALAMIN; CYCLOSPORIN; DIGOXIN; DISULFIRAM; ESOMEPRAZOLE; FLUINDOSTATIN; IMIPRAMINE; IRON; ITRACONAZOLE; KETOCONAZOLE; LANSOPRAZOLE; MAGNESIUM HYDROXIDE; METHOTREXATE; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PHENYTOIN; PROTON PUMP INHIBITOR; RABEPRAZOLE; SUCRALFATE; SULTAMICILLIN; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ARTICLE; DRUG INFORMATION; GENERAL PRACTICE; GENERAL PRACTITIONER; HUMAN; ITALY; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG INFORMATION SERVICES; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; FAMILY PRACTICE; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVER VARIATION; PRESCRIPTIONS, DRUG; PROTON PUMPS;

EID: 33749998907     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02687.x     Document Type: Article

References (37)

1. Jones R, Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ 1989; 298: 30-2.
2. van Bommel MJ, Numans ME, de Wit NJ, Stalman WA. Consultations and referrals for dyspepsia in general practice, a one year database survey. Postgrad Med J 2001; 77: 514-8.
3. Delaney BC, Innes MA, Deeks J, Wilson S, Oakes R, Moayyedi P, Hobbs FD, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst Rev 2000: (2): CD001961.
4. Blum RA. Lansoprazole and omeprazole in the treatment of acid peptic disorders. Am J Health-Syst Pharm 1996; 53: 1401-15.
5. Shin JM, Besancon M, Prinz C, Simon A, Sash G. Continuing development of acid pump inhibitors: site of action of pantoprazole. Aliment Pharmacol Ther 1994; 8: 11-23.
6. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 266-80.
7. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32: 821-7.
8. +-ATPase inhibitor pantoprazole (BY1023/SK and F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole. Biochem Pharmacol 1991; 42: 347-55.
9. Reilly JP. Safety profile of the proton-pump inhibitors. Am J Health Syst Pharm 1999; 56: S11-7.
10. Robinson M, Horn J. Clinical pharmacology of proton pump inhibitors: what the practising physician needs to know. Drugs 2003; 63: 2739-54.
11. Bergk V, Haefeli WE, Gasse C, Brenner H, Martin-Facklam M. Information deficits in the summary of product characteristics preclude an optimal management of drug interactions: a comparison with evidence from the literature. Eur J Clin Pharmacol 2005; 61: 327-35.
12. Klasko RK. ed. DRUGDEX System, 1st edn. Greenwood Village CO., Thomson Micromedex; 2003.
13. Piacentini N, Trifiro G, Tari M, Moretti S, Arcoraci V;UVEC, group. Statin-macrolide interaction risk: a population-based study throughout a general practice database. Eur J Clin Pharmacol 2005; 61: 615-20.
14. Lawrenson R, Williams T, Farmer R. Clinical information for research: the use of General Practice databases. J Public Health Med 1999, 21, 299-304.
15. Ibrahim IA, Kang E, Dansky KH. Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services. Home Health Care Serv Q 2005; 24: 87-99.
16. Altman DG. Practical statistics for medical research. Chapman & Hall; 1991.
17. Landis JR, Koch G. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-74.
18. Saltiel E, Fask A. Prevalence of potential proton-pump inhibitor drug interactions: a retrospective review of prescriptions in community pharmacies. Clin Ther 1999; 21: 1812-9.
19. Steinijans VW, Huber R, Hartmann M, Zech K, Bliesath H, Wurst W, Radtke HW. Lack of pantoprazole drug interactions in man. Int J Clin Pharmacol Ther 1994; 32: 385-99.
20. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole. an update of its pharmacological properties and therapeutic use in the management of acid-related disorders. Drugs 2003; 63: 101-33.
21. Meyer UA. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions. Yale J Biol Med 1996; 69: 203-9.
22. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13(Suppl 3): 18-26.
23. Janchawee B, Wongpoowarak W, Owatranporn T, Chongsuvivatwong V. Pharmacoepidemiologic study of potential drug interactions in outpatients of a University hospital in Thailand. J Clin Pharm Ther 2005; 30: 13-20.
24. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569-72.
25. Product Information. Nexium(™), esomeprazole. Willmington, DE, AstraZeneca; February 2001.
26. Product Information. Prevacid(®), lansoprazole. Lake Forest, IL, TAP Pharmaceuticals; August 2002.
27. Humphries TJ. A review of the drug-drug interaction potential of rabeprazole sodium based on CYP-450 interference or absorption effects. World Congress, Vienna, Austria, 1999.
28. 2 receptor blockers and proton pump inhibitors with warfarin in general practice. Postgrad Med J 1999; 75: 721-2.
29. Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, Paulsen O. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84.
30. Arranz R, Yanez E, Franceschi JL, Fernandez-Ranada JM. More about omeprazole-cyclosporine interaction. Am J Gastroenterol 1993; 88: 154.
31. Chen YF, Avery AJ, Neil KE, Johnson C, Dewey ME, Stockley IH. Incidence and possible causes of prescribing potentially hazardous/contraindicated drug combinations in general practice. Drug Saf 2005; 28: 67-80.
32. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458-70.
33. Abarca J, Malone DC, Armstrong EP, Grizzle AJ, Hansten PD, Van Bergen RC, Lipton RB. Concordance of severity ratings provided in four drug interaction compendia. J Am Pharm Assoc (Wash DC) 2004; 44: 136-41.
34. Chao SD, Maibach HI. Lack of drug interaction conformity in commonly used drug compendia for selected at-risk dermatologic drugs. Am J Clin Dermatol 2005; 6: 105-11.
35. Eames CH, Klein MS. Increasing access to clinical information on hospital wards. Proceedings of the Annu Symp Comput Appl Medical Care 1994, 981.
36. Bergk V, Gasse C, Rothenbacher D, Loew M, Brenner H, Haefeli WE. Drug interactions in primary care: impact of a new algorithm on risk determination. Clin Pharmacol Ther 2004; 76: 85-96.
37. Lee LS, Nafziger AN, Bertino JS Jr. Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered. Clin Pharmacol Ther 2005; 78: 1-6.